Form 13-F position report

PTC THERAPEUTICS INC

Reported by SG Americas Securities LLC

PTCT CUSIP 69366J200 Manager CIK 0001313360

Reported 15,455 shares, down 20,972 (57.6%) from the prior quarter.

Reported value -54.5%; share count -57.6% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q4 2021
Shares 15,455 Quarter-end amount reported
Reported value $616,000 Fair value at quarter end
Consecutive quarters held 12 Through Q4 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 1355000
2021-12-31 616000
2022-03-31 198000
2022-06-30 489000
2022-09-30 0
2022-12-31 161000
2023-03-31 1280000
2023-06-30 886000
2023-09-30 962000
2023-12-31 0
2024-09-30 835000
2024-12-31 0
2025-03-31 264000
2025-06-30 229000
2025-09-30 7984000
2025-12-31 67943000
2026-03-31 59934000
2026-06-30 49397000

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for PTC THERAPEUTICS INC held by SG Americas Securities LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 605,581 -274,120 (-31.2%) 0.03% $49,397,000 2026-08-07
Q1 2026 Reduced 879,701 -14,760 (-1.7%) 0.06% $59,934,000 2026-04-16
Q4 2025 Added 894,461 +764,364 (587.5%) 0.09% $67,943,000 2026-01-09
Q3 2025 Added 130,097 +125,417 (2679.9%) 0.03% $7,984,000 2025-10-23
Q2 2025 Reduced 4,680 -507 (-9.8%) < 0.01% $229,000 2025-08-08
Q1 2025 New 5,187 +5,187 (0.0%) < 0.01% $264,000 2025-04-15
Q4 2024 Reduced 0 -22,514 (-100.0%) 0 $0 2025-01-17
Q3 2024 New 22,514 +22,514 (0.0%) < 0.01% $835,000 2024-10-03
Q4 2023 Reduced 0 -42,949 (-100.0%) 0 $0 2024-01-12
Q3 2023 Added 42,949 +21,173 (97.2%) 0.01% $962,000 2023-10-13
Q2 2023 Reduced 21,776 -4,652 (-17.6%) < 0.01% $886,000 2023-07-10
Q1 2023 Added 26,428 +22,210 (526.6%) 0.01% $1,280,000 2023-04-28
Q4 2022 New 4,218 +4,218 (0.0%) < 0.01% $161,000 2023-02-02
Q3 2022 Reduced 0 -12,214 (-100.0%) 0 $0 2022-10-31
Q2 2022 Added 12,214 +6,897 (129.7%) < 0.01% $489,000 2022-07-29
Q1 2022 Reduced 5,317 -10,138 (-65.6%) < 0.01% $198,000 2022-04-29
Q4 2021 Reduced 15,455 -20,972 (-57.6%) < 0.01% $616,000 2022-02-07
Q3 2021 Added 36,427 +33,723 (1247.2%) < 0.01% $1,355,000 2021-11-01
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

198 managers reported PTC THERAPEUTICS INC for Q4 2021.

Managers reporting PTC THERAPEUTICS INC in Q4 2021.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 10,604,685 +13,954 0.03% $422,384,000 34 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 8,155,047 -611,780 0.05% $324,816,000 34 qtrs
VANGUARD GROUP INC Added 6,888,909 +130,935 < 0.01% $274,386,000 34 qtrs
BlackRock Inc Reduced 6,389,941 -112,792 < 0.01% $254,511,000 34 qtrs
RTW INVESTMENTS LP Unchanged 5,293,966 0 3.08% $210,859,000 21 qtrs
FRANKLIN RESOURCES INC Added 4,881,214 +68,157 0.07% $194,419,000 14 qtrs
JANUS HENDERSON GROUP PLC Added 3,901,397 +326,210 0.06% $155,397,000 12 qtrs
STATE STREET CORPORATION Added 2,801,431 +152,810 < 0.01% $111,581,000 34 qtrs
Bank of America Corporation Added 2,634,143 +2,352,106 0.01% $104,917,000 33 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 2,106,561 +1,501 < 0.01% $83,904,000 15 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2021
Filed
February 07, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
15,455
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.